Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and CCND1 Overexpression

Translocations involving CCND1 are well described in multiple myeloma (MM), most frequently t(11;14), but rearrangements involving the immunoglobulin kappa (IGK) locus are rare. We present a case of a 71-year-old female with MM harboring t(2;11)(p11.2;q13), resulting in IGK::CCND1, with cyclin D1 and BCL-2 overexpression. Her disease was refractory to multiple conventional therapies. On confirmation of this rearrangement by comprehensive genomic profiling, the decision was made to utilize a venetoclax-based regimen. The patient achieved a stringent complete response that has remained durable for over 3 years. This case highlights a novel and targetable genomic subtype of MM and reinforces the importance of molecular diagnostics in guiding precision therapy. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.